-
Something wrong with this record ?
Exploring the impact of sEH inhibition on intestinal cell differentiation and Colon Cancer: Insights from TPPU treatment
K. Koubova, Z. Tauber, K. Cizkova
Language English Country United States
Document type Journal Article
- MeSH
- Cell Differentiation * drug effects MeSH
- HT29 Cells MeSH
- Caco-2 Cells MeSH
- Cytoskeletal Proteins * metabolism MeSH
- Epoxide Hydrolases * antagonists & inhibitors metabolism MeSH
- Phenylurea Compounds pharmacology MeSH
- Enzyme Inhibitors pharmacology MeSH
- Humans MeSH
- p38 Mitogen-Activated Protein Kinases metabolism MeSH
- Colonic Neoplasms * drug therapy pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Inhibition of soluble epoxide hydrolase (sEH) appears to be promising for the treatment of many diseases. Studies have focused on the beneficial effects of epoxyeicosatrienoic acids (EETs), which are sEH substrates. However, our recent studies have shown that the sEH activity is crucial for the proper intestinal cell differentiation. In this recent study, we investigated the impact of TPPU, an inhibitor of sEH, on the colon cancer cell lines Caco2 and HT-29. We analysed the changes in the expression of the cytoskeletal protein ezrin and the phosphorylated protein kinase p38 (p-p38). Our results showed a decrease in ezrin expression in differentiated cells and an increase in p-p38 expression after TPPU treatment. Immunocytochemical staining revealed a higher staining intensity of p-p38 in the nuclei of HT-29 cells following TPPU treatment. Immunohistochemical staining was performed on human samples of normal colon tissue, grade 2 tumours, and embryonal/foetal tissues. The staining intensity of ezrin in tumours was reduced in the surface area compared to the crypts. Additionally, we observed the translocation of p-p38 expression from the cytoplasm to the nucleus during differentiation. The tumour samples exhibited higher levels of p-p38 in the cytoplasm, similar to normal undifferentiated tissue. To observe the disruption of the cytoskeleton after TPPU treatment, confocal microscopy was used. It was found that β-actin associated with ezrin forms clusters under the plasma membranes. All of these results are significant because sEH inhibitors are being tested in clinical trials, but they could cause an unexpected adverse effects.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003598
- 003
- CZ-PrNML
- 005
- 20250206104435.0
- 007
- ta
- 008
- 250121e20241015xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2024.117128 $2 doi
- 035 __
- $a (PubMed)39414156
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Koubova, Katerina $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
- 245 10
- $a Exploring the impact of sEH inhibition on intestinal cell differentiation and Colon Cancer: Insights from TPPU treatment / $c K. Koubova, Z. Tauber, K. Cizkova
- 520 9_
- $a Inhibition of soluble epoxide hydrolase (sEH) appears to be promising for the treatment of many diseases. Studies have focused on the beneficial effects of epoxyeicosatrienoic acids (EETs), which are sEH substrates. However, our recent studies have shown that the sEH activity is crucial for the proper intestinal cell differentiation. In this recent study, we investigated the impact of TPPU, an inhibitor of sEH, on the colon cancer cell lines Caco2 and HT-29. We analysed the changes in the expression of the cytoskeletal protein ezrin and the phosphorylated protein kinase p38 (p-p38). Our results showed a decrease in ezrin expression in differentiated cells and an increase in p-p38 expression after TPPU treatment. Immunocytochemical staining revealed a higher staining intensity of p-p38 in the nuclei of HT-29 cells following TPPU treatment. Immunohistochemical staining was performed on human samples of normal colon tissue, grade 2 tumours, and embryonal/foetal tissues. The staining intensity of ezrin in tumours was reduced in the surface area compared to the crypts. Additionally, we observed the translocation of p-p38 expression from the cytoplasm to the nucleus during differentiation. The tumour samples exhibited higher levels of p-p38 in the cytoplasm, similar to normal undifferentiated tissue. To observe the disruption of the cytoskeleton after TPPU treatment, confocal microscopy was used. It was found that β-actin associated with ezrin forms clusters under the plasma membranes. All of these results are significant because sEH inhibitors are being tested in clinical trials, but they could cause an unexpected adverse effects.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a buněčná diferenciace $x účinky léků $7 D002454
- 650 12
- $a nádory tračníku $x farmakoterapie $x patologie $7 D003110
- 650 _2
- $a buňky HT-29 $7 D019073
- 650 12
- $a epoxid hydrolasy $x antagonisté a inhibitory $x metabolismus $7 D004851
- 650 _2
- $a Caco-2 buňky $7 D018938
- 650 12
- $a cytoskeletální proteiny $x metabolismus $7 D003598
- 650 _2
- $a mitogenem aktivované proteinkinasy p38 $x metabolismus $7 D048051
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a fenylmočovinové sloučeniny $x farmakologie $7 D010671
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tauber, Zdenek $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Cizkova, Katerina $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic. Electronic address: katerina.cizkova@upol.cz
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 492 (20241015), s. 117128
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39414156 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104431 $b ABA008
- 999 __
- $a ok $b bmc $g 2263382 $s 1239605
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 492 $c - $d 117128 $e 20241015 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- LZP __
- $a Pubmed-20250121